Summary
This narrative review by Philip Calder synthesises evidence on the role of dietary polyunsaturated fatty acids — particularly long-chain omega-3 PUFAs (EPA and DHA) and omega-6 arachidonic acid — in modulating inflammatory processes implicated in inflammatory bowel diseases. The paper likely discusses mechanistic pathways through which PUFAs influence immune cell function, eicosanoid biosynthesis, and intestinal mucosal inflammation, drawing on in vitro, animal, and human intervention data. It contextualises these findings within the broader dietary imbalance of n-6 to n-3 fatty acids characteristic of Western diets and its potential contribution to chronic inflammatory conditions.
UK applicability
The review is broadly applicable to UK public health and clinical nutrition contexts, particularly given ongoing interest in dietary fat composition within NHS dietary guidelines and the relevance of IBD prevalence in the UK. Findings on omega-3 PUFA supplementation and dietary fat balance are pertinent to UK food policy and clinical dietary recommendations for IBD management.
Key measures
Inflammatory mediator profiles (eicosanoids, cytokines); omega-3 and omega-6 PUFA intake and tissue incorporation; clinical outcomes in IBD; n-3:n-6 fatty acid ratios
Outcomes reported
The paper examines how dietary polyunsaturated fatty acids (PUFAs), particularly omega-3 and omega-6 fatty acids, modulate inflammatory processes relevant to inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. It likely reviews the biochemical mechanisms by which PUFAs influence eicosanoid production, cytokine signalling, and gut mucosal inflammation.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.